Article

Is it ethical to reimburse “SMA Innovative Treatments” from government resources?

2023-12-29

Abstract excerpt

<title>Abstract</title> <p>Background Spinal Muscular Atrophy (SMA) is a rare genetic disorder that disturbs the quality of life. This paper aims to gather current understanding of safety, efficacy and economic aspects of common SMA treatments to help Iranian policy-makers to adopt such novel treatments for this vulnerable population. Methods This is a rapid health technology assessment (HTA) research that was...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c5bc924f-6db8-5c60-bc72-052aae405833
DOI: 10.21203/rs.3.rs-3795930/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Is it ethical to reimburse “SMA Innovative Treatments” from government resources?DOI 10.21203/rs.3.rs-3795930/v1Read

Spinal Muscular Atrophy: The High Costs of Innovative Therapies for Rare DiseasesSemantic proximity Read

Real world safety and exploratory efficacy of gene therapy for patients with 5q-Spinal Muscular Atrophy in a Brazilian cohortSemantic proximity Read

Rare Disease Curative Care Expenditure- Financing Scheme-Health Provider- Beneficiary Group Analysis — An Empirical Study in Sichuan Province, ChinaSemantic proximity Read

Deficiencies in the medical care of SMA: evidence from a nationwide patient registry in GermanySemantic proximity Read

Consensus from the Brazilian Academy of Neurology for the diagnosis, genetic counseling, and use of disease-modifying therapies in 5q spinal muscular atrophySemantic proximity Read

Treatment preference among patients with spinal muscular atrophy (SMA): a discrete choice experimentSemantic proximity Read

Epidemiology and economic burden of selected rare genetic diseases in Germany – a claims database studySemantic proximity Read

SPINAL MUSCULAR ATROPHY: CLINICAL CHARACTERIZATION AND EVOLUTION AFTER TREATMENT WITH NEW MODIFYING THERAPIESSemantic proximity Read

Spinal Muscular Atrophy Carrier Screening Program: Awareness and Attitude of Healthcare Professionals in TurkeySemantic proximity Read

Assessment of motor function and nutritional status in children with spinal muscular atrophy treated with nusinersen after loading period in western ChinaSemantic proximity Read

Gene-Based Therapy for the Treatment of Spinal Muscular Atrophy Types 1 and 2 : A Systematic Review and Meta-AnalysisSemantic proximity Read

Impact of Spinal Muscular Atrophy on Caregivers’ Daily Activities and Health-related Quality of LifeSemantic proximity Read